Acid-suppressive effect of tegoprazan 12.5 mg BID: a phase 1 comparative study with tegoprazan 25 mg QD and famotidine 20 mg BID
Ho-Sook Kim, Young-Kyung Choi, Minkyung Oh, Yong-Soon Cho, Jong-Lyul Ghim · 2025
Read Acid-suppressive effect of tegoprazan 12.5 mg BID: a phase 1 comparative study with tegoprazan 25 mg QD and famotidine 20 mg BID by Ho-Sook Kim, Young-Kyung Choi, Minkyung Oh, Yong-Soon Cho, Jong-Lyul Ghim (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12806658.txt.
Description
Ho-Sook Kim and co-authors compare three stomach acid regimens in healthy adults over fourteen days, in a phase one study from two thousand twenty-five. Thirty-six people took a low dose of tegoprazan twice a day, a higher dose once a day, or famotidine twice a day. Stomach pH was tracked around the clock.
The low twice-daily dose held acid down longest, keeping pH high for about three quarters of the day. The once-daily dose and famotidine trailed well behind by day fourteen. Famotidine also faded over time while both tegoprazan plans held steady. No side effects were reported in the low-dose group. Readers get a dosing case for split low doses.
Catalog record
| CREATOR | Ho-Sook Kim, Young-Kyung Choi, Minkyung Oh, Yong-Soon Cho, Jong-Lyul Ghim |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |